Acute myelocytic leukaemia associated with Kaposi's sarcoma in a patient without serum antibodies to human immunodeficiency virus type 1.
We report a 35-year-old man with acute myelocytic leukaemia and Kaposi's sarcoma, whose serum was non-reactive for antibodies to human immunodeficiency virus type-1 by enzyme-linked immunosorbent assay, Western blot and immunofluorescence. Complete remission of both the acute leukaemia and the Kaposi's sarcoma followed treatment with mitoxantrone and cytosine arabinoside. We speculate that the rapid regression of the lesions of Kaposi's sarcoma might be related to mitoxantrone and to the return to normal of his peripheral helper and suppressor T-cell counts.
Hernández
D E
DE
Department of Medicine, Universidad Central de Venezuela, Caracas.
Pellino
M L
ML
Ramírez
B
B
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001088:Arabinonucleotides / Q000627:therapeutic use; D003568:Cytidine Monophosphate / Q000031:analogs & derivatives / Q000627:therapeutic use; D015483:HIV Antibodies / Q000097:blood; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000150:complications* / Q000188:drug therapy / Q000276:immunology
D000970:Antineoplastic Agents; D001088:Arabinonucleotides; D015483:HIV Antibodies; C024888:1-beta-D-arabinofuranosylcytosine 5'-monophosphate; D008942:Mitoxantrone; D003568:Cytidine Monophosphate